Preclinical Sites At-a-Glance
Our recently AAALAC-accredited full-service facility in Edinburgh provides safety evaluation services, including toxicology and carcinogenicity studies, laboratory sciences and clinical support services. We can assist at all stages of drug development, from early-phase candidate screening to comprehensive regulatory development programs.
|
Charles River Laboratories International, Incorporated
251 Ballardvale St.
Wilmington, MA 01887
|
|
|
|
JET™: A Viable Alternative for Continuous Collection of Key Cardiovascular Data
With a power of 80% to detect down to 6 mmHg changes in blood pressure, Jacketed External Telemetry (JET™) can determine subtle hemodynamic changes while providing electrocardiographic (ECG) morphology and interval data that is equivalent to implanted telemetry. Learn more.
|
|
Minipigs: An Alternative Animal Model
A recent study from the European RETHINK Project recommended the minipig model be taken into account as a viable alternative nonrodent species in toxicity testing.
Charles River has background data, expertise and experience working with alternative nonrodent animal models. Available research methods include pharmacokinetic, safety pharmacology, and toxicity studies using various dose routes, including oral (gavage and pilling), intravenous and subcutaneous injections or infusion, as well as studies utilizing target tissue dosing and dermal and ocular (instillation, intravitreal and subretinal) administrations.
If you would like more information about utilizing alternative animal models, click here to contact a subject matter expert.
Related Information
- Poster: Background Incidence of Experimental-Related Events on Intravenous Infusion Studies in Minipigs
(Poster presented at the 2012 SOT meeting. Available only in The SourceSM. Click here to log in or click here to register.)
|
|
Get Faster Results with Accelerated Reporting of ADME Studies
In response to growing demand for faster reporting times, we have evaluated performance and processes for our in vitro and in vivo portfolio of ADME studies. We are delighted to announce accelerated reporting for many study types, including:
- Radiolabelled mass balance studies - fully QC-checked and peer-reviewed draft report within 7 days of final sample collection
- QWBA studies - fully QC-checked and peer-reviewed draft report within 14 days of sectioning of final animal
- In vitro CYP inhibition studies - fully QC-checked and peer-reviewed draft report within 21 days of study initiation
- In vitro CYP induction studies - fully QC-checked and peer-reviewed draft report within 14 days of receipt of final batch of human hepatocytes
Further accelerations and efficiencies can be made from abbreviated study designs or by combining studies into one protocol.
To learn more about how Charles River can create a customized ADME package for your development candidate, contact us at askcharlesriver@crl.com.
|
|
Through continuous innovation, we bring your program to approval in the most efficient and accelerated way possible. We offer compiled, audited draft reports at 10 weeks post necropsy (given standard program parameters) for studies up to and including 13 weeks of treatment across all Charles River preclinical facilities.
Here are resources available to better plan your programs:
|
|
|
